Filed Pursuant to Rule 424(b)(3)
Registration No. 333-84782
PROSPECTUS SUPPLEMENT
Number 13
to
Prospectus dated May 3, 2002, and Prospectus Supplements dated May 15, 2002,
September 10, 2002, November 21, 2002, April 1, 2003, May 20, 2003, June 19,
2003, August 20, 2003, November 18, 2003, March 30, 2004, May 20, 2004, November
17, 2004 and April 21, 2005,
of
NEOPROBE CORPORATION
5,898,876 Shares of Common Stock
This Prospectus Supplement relates to the sale of up to 5,898,876 shares of
Neoprobe Corporation common stock (the "Shares"). The Shares are being
registered to permit public secondary trading of the shares that are being
offered by the selling shareholders named in the prospectus. We are not selling
any of the Shares in this offering and therefore will not receive any proceeds
from this offering.
This Prospectus Supplement No. 13 includes the attached Quarterly Report on Form
10-QSB (the "Form 10-QSB") of Neoprobe Corporation (the "Company"), for the
quarter ended June 30, 2005, filed by the Company with the Securities and
Exchange Commission on August 15, 2005. The exhibits to the Form 10-QSB are not
included with this Prospectus Supplement No. 13 and are not incorporated by
reference herein. This Prospectus Supplement No. 13 should be read in
conjunction with the prospectus supplements dated May 15, 2002, September 10,
2002, November 21, 2002, April 1, 2003, May 20, 2003, June 19, 2003, August 20,
2003, November 18, 2003, March 30, 2004, May 20, 2004, November 17, 2004, and
April 21, 2005.
Our common stock is traded on the Over-the-Counter Bulletin Board under the
symbol "NEOP."
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE.
The date of this Prospectus Supplement No. 13 is August 24, 2005.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: June 30, 2005
or
[_] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE
EXCHANGE ACT
For the transition period from _______to________
Commission File Number: 0-26520
NEOPROBE CORPORATION
(Exact name of small business issuer as specified in its charter)
Delaware 31-1080091
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
425 Metro Place North, Suite 300, Dublin, Ohio 43017
(Address of principal executive offices)
614.793.7500
(Issuer's telephone number)
58,586,008 shares of common stock, par value $.001 per share
(Number of shares of issuer's common equity outstanding as of the
close of business on August 1, 2005)
Transitional Small Business Disclosure Format (check one) Yes |_| No |X|
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Neoprobe Corporation and Subsidiaries
Consolidated Balance Sheets
ASSETS June 30, December 31,
2005 2004
(unaudited)
----------- -----------
Current assets:
Cash and cash equivalents $ 4,574,985 $ 9,842,658
Available-for-sale securities 4,229,868 --
Accounts receivable, net 370,991 411,856
Inventory 756,907 855,022
Prepaid expenses and other 154,755 327,408
----------- -----------
Total current assets 10,087,506 11,436,944
----------- -----------
Property and equipment 2,380,471 2,341,785
Less accumulated depreciation and amortization 2,079,029 2,003,942
----------- -----------
301,442 337,843
----------- -----------
Patents and trademarks 3,163,897 3,155,334
Non-compete agreements 584,516 584,516
Acquired technology 237,271 237,271
----------- -----------
3,985,684 3,977,121
Less accumulated amortization 1,670,563 1,458,012
----------- -----------
2,315,121 2,519,109
----------- -----------
Other assets 975,567 1,071,999
----------- -----------
Total assets $13,679,636 $15,365,895
=========== ===========
Continued
2
Neoprobe Corporation and Subsidiaries
Consolidated Balance Sheets, continued
LIABILITIES AND STOCKHOLDERS' EQUITY June 30, December 31,
2005 2004
(unaudited)
--------------- ---------------
Current liabilities:
Notes payable to finance companies $ 87,825 $ 242,722
Accounts payable 418,362 198,912
Accrued liabilities and other 417,762 378,247
Capital lease obligations, current 17,585 13,863
Deferred revenue, current 311,843 176,192
--------------- ---------------
Total current liabilities 1,253,377 1,009,936
--------------- ---------------
Capital lease obligations 39,272 30,297
Deferred revenue 52,480 57,591
Notes payable to CEO, net of discounts of $29,373
and $32,204, respectively 70,627 67,796
Notes payable to investor, net of discounts of
$2,349,794 and $2,576,302, respectively 5,650,206 5,423,698
Liability related to warrants to purchase
common stock -- 2,560,307
Other liabilities 42,530 52,440
--------------- ---------------
Total liabilities 7,108,492 9,202,065
--------------- ---------------
Commitments and contingencies
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000
shares authorized at June 30, 2005 and
December 31, 2004; none issued and
outstanding (500,000 shares designated as
Series A, $.001 par value, at June 30,
2005 and and December 31, 2004; none
outstanding) -- --
Common stock; $.001 par value; 150,000,000
shares authorized, 58,585,008 shares
issued and outstanding at June 30, 2005;
100,000,000 shares authorized, 58,378,143
shares issued and outstanding at December
31, 2004 58,585 58,378
Additional paid-in capital 134,884,054 132,123,605
Accumulated deficit (128,365,335) (126,018,153)
Accumulated other comprehensive loss (6,160) --
--------------- ---------------
Total stockholders' equity 6,571,144 6,163,830
--------------- ---------------
Total liabilities and stockholders'
equity $ 13,679,636 $ 15,365,895
=============== ===============
See accompanying notes to the consolidated
3
financial statements.
Neoprobe Corporation and Subsidiaries
Consolidated Statements of Operations
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
---------------------------------- ----------------------------------
2005 2004 2005 2004
--------------- --------------- --------------- ---------------
Revenues:
Net sales $ 1,700,878 $ 1,347,928 $ 3,166,765 $ 2,573,545
License and other revenue -- 200,000 -- 400,000
--------------- --------------- --------------- ---------------
Total revenues 1,700,878 1,547,928 3,166,765 2,973,545
--------------- --------------- --------------- ---------------
Cost of goods sold 642,233 508,639 1,205,556 1,048,781
--------------- --------------- --------------- ---------------
Gross profit 1,058,645 1,039,289 1,961,209 1,924,764
--------------- --------------- --------------- ---------------
Operating expenses:
Research and development 1,303,369 594,730 1,941,814 1,177,830
Selling, general and administrative 827,832 853,149 1,663,947 1,666,542
--------------- --------------- --------------- ---------------
Total operating expenses 2,131,201 1,447,879 3,605,761 2,844,372
--------------- --------------- --------------- ---------------
Loss from operations (1,072,556) (408,590) (1,644,552) (919,608)
--------------- --------------- --------------- ---------------
Other income (expenses):
Interest income 67,916 4,824 108,879 5,357
Interest expense (333,905) (43,795) (661,478) (116,153)
Increase in warrant liability -- -- (142,427) --
Other (5,866) 17,688 (7,604) 11,954
--------------- --------------- --------------- ---------------
Total other expenses (271,855) (21,283) (702,630) (98,842)
--------------- --------------- --------------- ---------------
Net loss $ (1,344,411) $ (429,873) $ (2,347,182) $ (1,018,450)
=============== =============== =============== ===============
Net loss per common share:
Basic $ (0.02) $ (0.01) $ (0.04) $ (0.02)
Diluted $ (0.02) $ (0.01) $ (0.04) $ (0.02)
Weighted average shares outstanding:
Basic 58,455,008 57,727,298 58,386,434 55,388,205
Diluted 58,455,008 57,727,298 58,386,434 55,388,205
See accompanying notes to the consolidated
4
financial statements.
Neoprobe Corporation and Subsidiaries
Consolidated Statements of Cash Flows
(unaudited)
Six Months Ended
June 30,
--------------------------
2005 2004
----------- -----------
Cash flows from operating activities:
Net loss $(2,347,182) $(1,018,450)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 300,560 296,520
Amortization of debt discount and offering costs 329,611 95,557
Increase in warrant liability 142,427 --
Other 2,450 79,896
Changes in operating assets and liabilities:
Accounts receivable 40,865 536,508
Inventory 84,596 4,534
Prepaid expenses and other assets 201,739 108,472
Accounts payable 219,450 111,304
Accrued liabilities and other liabilities 29,585 88,348
Deferred revenue 130,540 (515,242)
----------- -----------
Net cash used in operating activities (865,359) (212,553)
----------- -----------
Cash flows from investing activities:
Purchases of available-for-sale securities (4,744,030) --
Proceeds from maturities of available-for-sale securities 500,000 --
Purchases of property and equipment (45,743) (42,935)
Proceeds from sales of property and equipment 11,855 375
Patent and trademark costs (10,898) (12,108)
----------- -----------
Net cash used in investing activities (4,288,816) (54,668)
----------- -----------
Cash flows from financing activities:
Proceeds from issuance of common stock 57,922 2,293,073
Payment of offering costs -- (16,423)
Payment of debt issuance costs (9,635) --
Payment of notes payable (154,897) (158,544)
Payments under capital leases (6,908) (9,503)
Minority interest in subsidiary 20 --
----------- -----------
Net cash (used in) provided by financing activities (113,498) 2,108,603
----------- -----------
Net (decrease) increase in cash and cash equivalents (5,267,673) 1,841,382
Cash and cash equivalents, beginning of period 9,842,658 1,588,760
----------- -----------
Cash and cash equivalents, end of period $ 4,574,985 $ 3,430,142
=========== ===========
See accompanying notes to the consolidated financial statements.
5
Notes to the Consolidated Financial Statements
(unaudited)
1. Basis of Presentation
The information presented as of June 30, 2005 and 2004 and for the periods
then ended is unaudited, but includes all adjustments (which consist only
of normal recurring adjustments) that the management of Neoprobe
Corporation (Neoprobe, the company, or we) believes to be necessary for
the fair presentation of results for the periods presented. Certain
information and footnote disclosures normally included in financial
statements prepared in accordance with U.S. generally accepted accounting
principles have been condensed or omitted pursuant to the rules and
regulations of the U.S. Securities and Exchange Commission. The results
for the interim periods are not necessarily indicative of results to be
expected for the year. The consolidated financial statements should be
read in conjunction with Neoprobe's audited consolidated financial
statements for the year ended December 31, 2004, which were included as
part of our Annual Report on Form 10-KSB.
Our consolidated financial statements include the accounts of Neoprobe,
our wholly-owned subsidiary, Cardiosonix Ltd. (Cardiosonix), and our
90%-owned subsidiary, CIRA Biosciences, Inc. (CIRA Bio). All significant
inter-company accounts were eliminated in consolidation.
2. Stock Options
The following table illustrates the effect on net loss and net loss per
share if compensation cost for our stock-based compensation plans had been
determined based on the fair value at the grant dates for awards under
those plans consistent with Statement of Financial Accounting Standards
(SFAS) No. 123, Accounting for Stock-Based Compensation:
Three Months Ended
June 30,
-----------------------------
2005 2004
----------- -----------
Net loss, as reported $(1,344,411) $ (429,873)
Deduct: Total stock-based employee
compensation expense determined under
fair value based method for all awards (91,470) (69,847)
----------- -----------
Pro forma net loss $(1,435,881) $ (499,720)
=========== ===========
Loss per common share:
As reported (basic and diluted) $ (0.02) $ (0.01)
Pro forma (basic and diluted) $ (0.02) $ (0.01)
Six Months Ended
June 30,
------------------------------
2005 2004
------------- -------------
Net loss, as reported $ (2,347,182) $ (1,018,450)
Deduct: Total stock-based employee
compensation expense determined under
fair value based method for all awards (305,770) (132,621)
------------- -------------
Pro forma net loss $ (2,652,952) $ (1,151,071)
============= =============
Loss per common share:
As reported (basic and diluted) $ (0.04) $ (0.02)
Pro forma (basic and diluted) $ (0.05) $ (0.02)
6
During the first six months of 2005, the Board of Directors granted
options to directors and certain employees to purchase 338,000 shares of
our common stock, exercisable at an average price of $0.67 per share,
vesting over three years. As of June 30, 2005, we have 5.0 million options
outstanding under three stock option plans. Of the outstanding options,
3.0 million options have vested as of June 30, 2005, at an average
exercise price of $0.47 per share.
3. Comprehensive Income (Loss)
Due to our net operating loss position, there are no income tax effects on
comprehensive income (loss) components for the three-month and six-month
periods ended June 30, 2005.
Three Months Six Months
Ended Ended
June 30, 2005 June 30, 2005
--------------- ---------------
Net loss $ (1,344,411) $ (2,347,182)
Unrealized losses on securities (3,962) (6,160)
--------------- ---------------
Other comprehensive loss $ (1,348,373) $ (2,353,342)
=============== ===============
We had no accumulated other comprehensive income (loss) activity during
the three-month and six-month periods ended June 30, 2004.
4. Earnings Per Share
Basic earnings (loss) per share is calculated using the weighted average
number of common shares outstanding during the periods. Diluted earnings
(loss) per share is calculated using the weighted average number of common
shares outstanding during the periods, adjusted for the effects of
convertible securities, options and warrants, if dilutive.
Three Months Ended Three Months Ended
June 30, 2005 June 30, 2004
-------------------------- ---------------------------
Basic Diluted Basic Diluted
Earnings Earnings Earnings Earnings
Per Share Per Share Per Share Per Share
----------- ----------- ----------- -----------
Outstanding shares 58,585,008 58,585,008 58,087,057 58,087,057
Effect of weighting changes
in outstanding shares -- -- (229,759) (229,759)
Contingently issuable shares (130,000) (130,000) (130,000) (130,000)
----------- ----------- ----------- -----------
Adjusted shares 58,455,008 58,455,008 57,727,298 57,727,298
=========== =========== =========== ===========
Six Months Ended Six Months Ended
June 30, 2005 June 30, 2004
------------------------ ---------------------------
Basic Diluted Basic Diluted
Earnings Earnings Earnings Earnings
Per Share Per Share Per Share Per Share
----------- ----------- ----------- -----------
Outstanding shares 58,585,008 58,585,008 58,087,057 58,087,057
Effect of weighting changes
in outstanding shares (68,574) (68,574) (2,568,852) (2,568,852)
Contingently issuable shares (130,000) (130,000) (130,000) (130,000)
----------- ----------- ----------- -----------
Adjusted shares 58,386,434 58,386,434 55,388,205 55,388,205
=========== =========== =========== ===========
7
There is no difference in basic and diluted loss per share related to the
three-month and six-month periods ended June 30, 2005 and 2004. The net
loss per common share for these periods excludes the number of common
shares issuable upon exercise of outstanding stock options and warrants
into our common stock or upon the conversion of convertible debt since
such inclusion would be anti-dilutive.
5. Available-for-Sale Securities
Available-for-sale securities are recorded at fair value. Unrealized
holding gains and losses, net of the related tax effect, on
available-for-sale securities are excluded from earnings and are reported
as a separate component of other comprehensive income (loss) until
realized. Realized gains and losses from the sale of available-for-sale
securities are determined on a specific identification basis.
A decline in the market value of any available-for-sale security below
cost that is deemed to be other than temporary results in a reduction in
carrying amount to fair value. The impairment is charged to earnings and a
new cost basis for the security is established. Premiums and discounts are
amortized or accreted over the life of the related available-for-sale
security as an adjustment to yield using the effective interest method.
Dividend and interest income are recognized when earned.
Available-for-sale securities are classified as current based on our
intent to use them to fund short-term working capital needs.
6. Inventory
The components of inventory are as follows:
June 30, December 31,
2005 2004
(unaudited)
--------------- ---------------
Materials and component parts $ 536,635 $ 486,323
Finished goods 220,272 368,699
--------------- ---------------
$ 756,907 $ 855,022
=============== ===============
7. Intangible Assets
The major classes of intangible assets are as follows:
June 30, 2005 December 31, 2004
(unaudited)
------------------------------- -------------------------------
Gross Carrying Accumulated Gross Carrying Accumulated
Amount Amortization Amount Amortization
-------------- -------------- -------------- --------------
Patents and trademarks $ 3,163,897 $ 1,039,010 $ 3,155,334 $ 915,571
Non-compete agreements 584,516 512,263 584,516 440,005
Acquired technology 237,271 119,290 237,271 102,436
-------------- -------------- -------------- --------------
$ 3,985,684 $ 1,670,563 $ 3,977,121 $ 1,458,012
============== ============== ============== ==============
8
The estimated future amortization expenses for the next five fiscal years are as
follows:
Estimated
Amortization
Expense
----------------
For the year ended 12/31/2005 $ 423,524
For the year ended 12/31/2006 267,576
For the year ended 12/31/2007 235,237
For the year ended 12/31/2008 205,170
For the year ended 12/31/2009 170,940
8. Product Warranty
We warrant our products against defects in design, materials, and
workmanship generally for a period of one year from the date of sale to
the end customer. Our accrual for warranty expenses is adjusted
periodically to reflect actual experience. Our primary marketing partner,
Ethicon Endo-Surgery, Inc. (EES), a Johnson and Johnson company, also
reimburses us for a portion of warranty expense incurred based on end
customer sales they make during a given fiscal year. Payments charged
against the reserve are disclosed net of EES' reimbursement.
The activity in the warranty reserve account for the three-month and
six-month periods ended June 30, 2005 and 2004 is as follows:
Three Months Ended Six Months Ended
June 30, June 30,
---------------------------- ----------------------------
2005 2004 2005 2004
------------ ------------ ------------ ------------
Warranty reserve at
beginning of period $ 66,500 $ 53,000 $ 66,000 $ 53,000
Provision for warranty claims and
changes in reserve for warranties 7,040 (7,000) 30,613 (7,000)
Payments charged against the
reserve (24,945) -- (48,018) --
------------ ------------ ------------ ------------
Warranty reserve at end of period $ 48,595 $ 46,000 $ 48,595 $ 46,000
============ ============ ============ ============
9. Notes Payable
In December 2004, we completed a private placement of four-year
convertible promissory notes in an aggregate principal amount of $8.1
million with Biomedical Value Fund, L.P., Biomedical Offshore Value Fund,
Ltd. and David C. Bupp (our President and CEO). Biomedical Value Fund,
L.P. and Biomedical Offshore Value Fund, Ltd. are funds managed by Great
Point Partners, LLC. The notes bear interest at 8% per annum, payable
quarterly on each March 31, June 30, September 30 and December 31 of each
year, and are freely convertible into shares of our common stock at a
price of $0.40 per share. Neoprobe may force conversion of the notes prior
to their stated maturity under certain circumstances. All of our material
assets, except the intellectual property associated with our LymphoseekTM
and RIGS(R) products under development, have been pledged as collateral
for these notes.
In addition to the security interest in our assets, the notes carry
substantial covenants that impose significant requirements on us,
including, among others, requirements that: we pay all principal, interest
and other charges on the notes when due; we use the proceeds from the sale
of the notes only for permitted purposes such as Lymphoseek development
and general corporate purposes; we nominate and recommend for election as
a director a person designated by the holders of the notes (as of June 30,
9
2005, the holders of the notes have not designated a potential board
member); we keep reserved out of our authorized shares of common stock
sufficient shares to satisfy our obligation to issue shares on conversion
of the notes and the exercise of the warrants issued in connection with
the sale of the notes; we achieve annual revenues on a consolidated basis
of at least $5.4 million in 2005, $6.5 million in 2006, and $9.0 million
in each year thereafter; we maintain minimum cash and securities balances
of $4.5 million at the end of the first six months of 2005, $4.0 million
at the end of the second six months of 2005, and $3.5 million at the end
of each six-month period thereafter; and we indemnify the purchasers of
the notes against certain liabilities. Additionally, with certain
exceptions, the notes prohibit us from: amending our organizational or
governing agreements and documents, entering into any merger or
consolidation, dissolving the company or liquidating its assets, or
acquiring all or any substantial part of the business or assets of any
other person; engaging in transactions with any affiliate; entering into
any agreement inconsistent with our obligations under the notes and
related agreements; incurring any indebtedness, capital leases, or
contingent obligations outside the ordinary course of business; granting
or permitting liens against or security interests in our assets; making
any material dispositions of our assets outside the ordinary course of
business; declaring or paying any dividends or making any other restricted
payments; or making any loans to or investments in other persons outside
of the ordinary course of business.
As part of this transaction, we issued the investors 10,125,000 Series T
warrants to purchase our common stock at an exercise price of $0.46,
expiring in December 2009. The fair value of the warrants issued to the
investors was $1,315,000 on the date of issuance and was determined by a
third-party valuation expert using the Black-Scholes option pricing model
with the following assumptions: an average risk-free interest rate of
3.4%, volatility of 50% and no expected dividend rate. In connection with
this financing, we also issued 1,600,000 warrants to purchase our common
stock to the placement agents, containing substantially the same terms as
the warrants issued to the investors. The fair value of the warrants
issued to the placement agents was $208,014 using the Black-Scholes option
pricing model with the same assumptions used to determine the fair value
of the warrants issued to the investors. The value of the beneficial
conversion feature of the notes was estimated at $1,315,000 based on the
effective conversion price at the date of issuance. The fair value of the
warrants issued to the investors and the value of the beneficial
conversion feature were recorded as discounts on the notes and are being
amortized over the term of the notes using an effective interest rate of
19.8%. The fair value of the warrants issued to the placement agents was
recorded as a deferred debt issuance cost and is being amortized over the
term of the notes. If we issue equity at prices below the conversion rate
for the promissory notes (and for the warrants below the exercise price),
then we would be required to reset the exercise and conversion prices for
these securities. This provision results in a contingent beneficial
conversion feature that may require us to estimate an additional debt
discount if a reset occurs.
U.S. generally accepted accounting principles also required us to classify
the warrants issued in connection with the placement as a liability due to
penalty provisions contained in the securities purchase agreement. The
penalty provisions could have required us to pay a penalty of 0.0667% per
day of the total debt amount if we failed to meet certain registration
deadlines, or if our stock was suspended from trading for more than 30
days. As a liability, the warrants were considered a derivative instrument
that were required to be periodically "marked to market" on our
consolidated balance sheet. We estimated the fair value of the warrants at
December 31, 2004 using the Black-Scholes option pricing model with the
following assumptions: an average risk-free interest rate of 3.4%,
volatility of 50% and no expected dividend rate. On February 16, 2005,
Neoprobe and the investors confirmed in writing their intention that the
penalty provisions which led to this accounting treatment were intended to
apply only to the $8.1 million principal balance of the promissory notes
and underlying conversion shares and not to the warrant shares. Because
the value of our stock increased $0.02 per share from $0.59 per share at
December 31, 2004 to $0.61 per share at February 16, 2005, the effect of
marking the warrant liability to "market" resulted in an increase in the
estimated fair value of the warrant liability of $142,427 which was
recorded as non-cash expense during the first quarter of 2005. The
estimated fair value of the warrant liability was then reclassified to
additional paid-in capital during the first quarter of 2005.
10
10. Stock Warrants
During the first six months of 2005, 143,278 of our Series R and 63,587 of
our Series S warrants that were issued in October 2003 were exercised and
we realized net proceeds of $57,922.
At June 30, 2005 there are 17.0 million warrants outstanding to purchase
our common stock. The warrants are exercisable at prices ranging from
$0.13 to $0.75 per share with a weighted average exercise price $0.40 per
share.
11. Segment and Subsidiary Information
We own or have rights to intellectual property involving two primary types
of medical device products, including gamma detection instruments
currently used primarily in the application of intraoperative lymphatic
mapping (ILM), and blood flow measurement devices. We also own or have
rights to intellectual property related to several drug and therapy
products.
The information in the following table is derived directly from each
segment's internal financial reporting used for corporate management
purposes. Selling, general and administrative expenses and other expenses,
including amortization, interest and other costs that relate primarily to
corporate activity, are not currently allocated to the operating segments
for financial reporting purposes.
Gamma Blood Flow Drug and
($ amounts in thousands) Detection Devices Therapy
Three Months Ended June 30, 2005 Devices Products Unallocated Total
----------------------------------------- -------------- ------------- ------------ --------------- ------------
Net sales:
United States(1) $ 1,596 $ - $ - $ - $ 1,596
International 16 89 - - 105
Research and development expenses 84 390 829 - 1,303
Selling, general and administrative
expenses - - - 828 828
Income (loss) from operations(2) 918 (334) (829) (828) (1,073)
Other expenses - - - (272) (272)
Three Months Ended June 30, 2004
-----------------------------------------
Net sales:
United States(1) $ 1,321 $ - $ - $ - $ 1,321
International 27 - - - 27
License and other revenue 200 - - - 200
Research and development expenses 140 335 120 - 595
Selling, general and administrative
expenses - - - 853 853
Income (loss) from operations(2) 955 (391) (120) (853) (409)
Other expenses - - - (21) (21)
11
Gamma Blood Flow Drug and
($ amounts in thousands) Detection Devices Therapy
Six Months Ended June 30, 2005 Devices Products Unallocated Total
----------------------------------------- -------------- ------------- ------------ --------------- ------------
Net sales:
United States(1) $ 2,950 $ 56 $ - $ - $ 3,006
International 58 103 - - 161
Research and development expenses 122 740 1,080 - 1,942
Selling, general and administrative
expenses - - - 1,664 1,664
Income (loss) from operations(2) 1,745 (646) (1,080) (1,664) (1,645)
Other expenses - - - (703) (703)
Six Months Ended June 30, 2004
-----------------------------------------
Net sales:
United States(1) $ 2,486 $ - $ - $ - $ 2,486
International 50 38 - - 88
License and other revenue 400 - - - 400
Research and development expenses 281 669 228 - 1,178
Selling, general and administrative
expenses - - - 1,667 1,667
Income (loss) from operations(2) 1,675 (700) (228) (1,667) (920)
Other expenses - - - (99) (99)
(1) All sales to EES are made in the United States. EES distributes the
product globally through its international affiliates.
(2) Income (loss) from operations does not reflect the allocation of
selling, general and administrative expenses to the operating
segments.
12. Supplemental Disclosure for Statements of Cash Flows
During the first six months of 2005 and 2004, we paid interest aggregating
$332,000 and $19,000, respectively. During the first six months of 2005
and 2004, we purchased equipment under capital leases totaling $20,000 and
$27,000, respectively. During the first six months of 2004, an outside
investor converted the entire balance of a $250,000 note into 1.1 million
shares of our common stock. Also during the first six months of 2004,
certain warrant holders exercised 173,544 warrants on a cashless basis in
exchange for 116,571 shares of common stock.
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
Neoprobe Corporation is a biomedical technology company that provides innovative
surgical and diagnostic products that enhance patient care by meeting the
critical decision-making needs of physicians. The December 2001 acquisition of
Cardiosonix Ltd. (Cardiosonix) expanded our potential product offerings beyond
the neo2000 gamma detection device, which is marketed in the oncology arena,
into the area of blood flow measurement and cardiac care. Cardiosonix is
commercializing a unique line of proprietary blood flow monitoring devices for a
variety of diagnostic and surgical applications and has received marketing
clearance for two of its products, Quantix/ND(TM) and Quantix/OR(TM), in Europe
and in the U.S. In addition to our medical device products, we have two
radiopharmaceutical products, Lymphoseek(TM) and RIGScan(R) CR, in the advanced
phases of clinical development. In January 2005 we also formed a new subsidiary,
CIRA Biosciences, Inc. (CIRA Bio) to advance our activated cellular therapy
(ACT) platform.
This Overview section contains a number of forward-looking statements, all of
which are based on current expectations. Actual results may differ materially
from the anticipated results discussed herein. Our financial performance is
highly dependent on our ability to continue to generate income and cash flow
from our gamma device product line and on our ability to successfully
commercialize the blood flow products of our subsidiary,
12
Cardiosonix. We cannot assure you that we will achieve the volume of sales
anticipated, or if achieved, that the margin on such sales will be adequate to
produce positive operating cash flow. We continue to be optimistic about the
longer-term potential for our other proprietary, procedural-based technologies
such as Lymphoseek, RIGS(R) (radioimmunoguided surgery) and ACT; however, these
technologies are not anticipated to generate any significant revenue for us
during 2005 or 2006. In addition, we cannot assure you that these products will
ever obtain marketing clearance from the appropriate regulatory bodies.
Our revenue for the first six months of 2005 was somewhat higher than our
original expectations. Unit sales of our gamma detection devices year-to-date
were consistent with our expectations; however, we experienced both an increase
in average sales prices and higher than normal sales of extended service
agreements during the period. Our sales of blood flow measurement devices
represents a combination of demonstration and customer unit sales following the
launch of a redesigned Quantix/OR device late in the first quarter of 2005. We
continue to expect net sales of gamma detection devices for 2005 to be
consistent with 2004 and that our sales of blood flow measurement devices will
continue to increase during the second half of 2005 over the first half of the
year. However, due to the time necessary to retrain our distributor base as well
as the normal capital product sales cycle, sales of Quantix(R) devices during
the remainder of 2005 are more likely to be weighted in the fourth quarter and
are still highly dependent upon physician response to the product.
Our operating expenses during the first six months of 2005 were focused
primarily on support for our Lymphoseek product development. In addition, we
continued to make significant investments in CIRA Bio's ACT technology and our
Quantix blood flow measurement line as well as modest investments in our
neo2000(R) gamma detection device product line. We expect our development
expenses to increase over the remainder of 2005 as we complete non-clinical
testing, conclude certain drug manufacturing and validation activities and
prepare to begin multi-center clinical evaluation of Lymphoseek. We expect to
continue to incur development expenses to support and innovate our device
product lines as well as move our other initiatives forward. We will also
continue to invest in marketing and development support for our blood flow
products during 2005 as we work with our distribution partners and independent
sales representatives to complete the commercialization of our Quantix product
lines.
Our efforts thus far in 2005 have resulted in the following milestone
achievements:
o Received 501(k) and CE Mark clearances to market the redesigned Quantix/OR
system;
o Established corporate Investigational New Drug (IND) application for
Lymphoseek and submitted multi-center clinical protocol and related
materials to FDA under the IND;
o Received initial feedback to the Lymphoseek IND from the FDA;
o Licensed methodology patents strengthening RIGS intellectual property
estate;
o Expanded Lymphoseek license to cover photodynamic and ultrasound
applications; and
o Received positive independent technology assessment of CIRA Bio's ACT
platform.
We are in the process of completing certain pre-clinical and animal testing
requested by the FDA in their feedback to our Lymphoseek IND submission. We
expect these pre-clinical studies to be completed within the next 30 days.
Following the FDA's review of the pre-clinical results, we expect to begin
enrollment in a Phase II multi-center study at five leading cancer centers in
the U.S. The Phase II study is expected to be completed midway through the
fourth quarter of 2005. We are also continuing our manufacturing scale-up and
validation activities to support the upcoming clinical trials. As a result of
these activities, we expect our development expenses related to Lymphoseek to
increase over the remainder of 2005 and into 2006, although we continue to
believe our estimate of $5 million in out-of-pocket development costs remains
appropriate. Our overall timeline for Lymphoseek remains focused on completing
the Phase II study followed by a pivotal clinical trial to support our goal of
filing a New Drug Application (NDA) for Lymphoseek by mid-2006.
With respect to our RIGS initiative, our current efforts are focused on
identifying and securing a development partner. At present, we estimate the
expenses to prepare for and conduct a Phase III clinical trial for RIGScan CR
will total approximately $25 million. However, expenses for
13
these projects may change based on feedback from the regulatory agencies and/or
modifications made to trial designs. It remains our intent to seek a development
partner to assist in or take full responsibility for funding of RIGScan CR
development. In the meantime, until a partner is secured, we are moving forward
with our plans to submit a request for a special protocol assessment (SPA)
related to RIGS; however, we do not expect to incur any significant additional
expenses related to RIGS until a partner is secured.
The commercial manufacturing assessment recently completed by the Battelle
Memorial Institute related to CIRA Bio's ACT technology coupled with the
clinical strategy recommendations recently made by CIRA Bio's scientific
advisors have set the stage for CIRA Bio to embark on capital-raising efforts,
which we expect to begin during the third quarter as we look to move the
platform forward.
We anticipate generating a net profit from the sale of our gamma detection
devices in 2005; however, we expect to show a loss for our blood flow device
product line for 2005 due to continued development and increased marketing and
administrative support costs that are still required to commercialize the
product line. Currently, we expect the loss on blood flow products for 2005 to
be less than the loss incurred in 2004. However, this expectation is based to a
large degree on our anticipation that we will achieve greater commercial sales
of our Quantix/OR product during the remainder of 2005 than in 2004.
Our overall operating results for 2005 will be significantly affected by the
amount of development costs associated with the radiopharmaceutical products. If
we are unsuccessful in achieving significant commercial sales of the Quantix/OR
product in 2005, or if we modify our business plan and decide to carry out RIGS
development internally, our estimates and our business plan will likely need to
be modified. As a result of our decision to fund Lymphoseek development
internally, we do not expect to achieve operating profit during 2005. In
addition, our net loss and net loss per share will likely be significantly
impacted by the non-cash interest expense we expect to record related to the
accounting treatment for the beneficial conversion feature of the convertible
debt and for the warrants issued in connection with the private placement we
completed in December 2004. Also, we cannot assure you that our current or
potential new products will be successfully commercialized, that we will achieve
significant product revenues, or that we will achieve or be able to sustain
profitability in the future.
Results of Operations
Revenue for the first six months of 2005 increased $193,000, or 6%, to $3.2
million from $3.0 million for the same period in 2004. Net sales for the first
six months of 2005 increased $593,000, or 23%, to $3.2 million from $2.6 million
for the same period in 2004. Research and development expenses, as a percentage
of net sales, increased to 61% during the first six months of 2005 from 46%
during the same period in 2004. Selling, general and administrative expenses, as
a percentage of net sales, decreased to 53% during the first six months of 2005
from 65% during the same period in 2004. Due to the ongoing drug and therapeutic
development activities of the company, research and development expenses are
expected to continue to be higher as a percentage of sales in 2005 than they
were in 2004. In addition, marketing and selling expenses, coupled with
increased financial compliance, investor relations and professional services
costs, are expected to push our overall selling, general and administrative
expenses slightly higher in 2005 than 2004 as a percentage of sales.
Three Months Ended June 30, 2005 and 2004
Net Sales and Margins. Net sales, primarily comprised of our gamma detection
systems, increased $353,000, or 26%, to $1.7 million during the second quarter
of 2005 from $1.3 million during the same period in 2004. Gross margins on net
sales remained steady at 62% of net sales for the second quarters of 2005 and
2004. The increase in net sales was the combined result of a modest
strengthening in gamma detection device sales prices in the U.S. and Europe
partially influenced by the strong Euro exchange rate that continued through
mid-year 2005, and increased extended service contract sales activity
experienced by our primary gamma detection device marketing partner. Gross
margin percentages remained steady but were influenced primarily by the increase
in sales prices and unit sales volumes, coupled with increased extended service
contract sales which typically generate higher margins than sales of our
devices, and offset by slightly increased unit costs to manufacture our neo2000
control unit.
14
License and Other Revenue. License and other revenue in the second quarter of
2004 included $200,000 from the pro-rata recognition of license fees related to
the distribution agreement with Ethicon Endo-Surgery, Inc. (EES), a Johnson and
Johnson company. These license fees were fully amortized into income as of the
end of the third quarter of 2004, so there were no such revenues recorded in the
second quarter of 2005.
Research and Development Expenses. Research and development expenses increased
$709,000 or 119% to $1.3 million during the second quarter of 2005 from $595,000
during the same period in 2004. The increase was primarily due to efforts to
move forward with development activities related to our Quantix devices,
Lymphoseek, the ACT technology platform of our CIRA Bio subsidiary, and
increased headcount in the U.S., offset by decreased expenses related to our
gamma detection devices, RIGS development, and declines in Israeli personnel.
The second quarter of 2004 included significant development activities related
to an updated version of our neo2000 system and product development activities
related to the Quantix/OR. Research and development expenses in the second
quarter of 2005 included approximately $84,000 in gamma detection device
development costs, $390,000 in product design activities for the Quantix/OR
system and $829,000 in drug and therapy product development costs. This compares
to expenses of $140,000, $335,000 and $120,000 in these relative segment
categories during the same period in 2004.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses decreased $25,000 or 3% to $828,000 during the second
quarter of 2005 from $853,000 during the same period in 2004. Increases in
certain overhead costs such as investor relations and depreciation coupled with
increased headcount in the U.S. were offset by decreased marketing expenses.
Other Income (Expenses). Other expenses increased $251,000 to $272,000 during
the second quarter of 2005 from $21,000 during the same period in 2004. The
primary reason for the increase was an increase of $290,000 in interest-related
expenses on debt financings we entered into during 2004. Of this interest
expense, $168,000 and $35,000 in the second quarter of 2005 and 2004,
respectively, was non-cash in nature related to the amortization of debt
issuance costs and discounts resulting from the warrants and beneficial
conversion features of the convertible debt. These increases were offset by an
increase of $63,000 in interest income resulting from maintaining a higher
balance of cash and investments during the second quarter of 2005 compared to
the same period in 2004.
Six Months Ended June 30, 2005 and 2004
Net Sales and Margins. Net sales, primarily of our gamma detection systems,
increased $593,000, or 23%, to $3.2 million during the first six months of 2005
from $2.6 million during the same period in 2004. Gross margins on net sales
increased to 62% of net sales for the first six months of 2005 compared to 59%
of net sales for the same period in 2004. The increase in net sales was the
combined result of a modest strengthening in gamma detection device sales prices
in the U.S. and Europe partially influenced by the strong Euro exchange rate and
increased extended service contract sales activity experienced by our primary
gamma detection device marketing partner. Gross margin percentages remained
steady but were influenced by the increase in sales prices, coupled with
increased extended service contract sales which typically generate higher
margins than sales of our devices, and partially offset by slightly increased
unit costs to manufacture our neo2000 control unit.
License and Other Revenue. License and other revenue in the first six months of
2004 included $400,000 from the pro-rata recognition of license fees related to
the distribution agreement with EES. These license fees were fully amortized
into income as of the end of the third quarter of 2004, so there were no such
revenues recorded in the first six months of 2005.
Research and Development Expenses. Research and development expenses increased
$764,000 or 65% to $1.9 million during the first six months of 2005 from $1.2
million during the same period in 2004. The increase was primarily due to
efforts to move forward with development activities related to Lymphoseek, the
15
ACT technology platform of our CIRA Bio subsidiary, and increased headcount in
the U.S., offset by decreased expenses related to our gamma detection devices,
RIGS development, and Quantix. The first six months of 2004 included final
development activities related to an updated version of our neo2000 system and
product development activities related to the Quantix/OR. Research and
development expenses in the first six months of 2005 included approximately
$122,000 in gamma detection device development costs, $740,000 in product design
activities for the Quantix/OR system and $1.1 million in drug and therapy
product development costs. This compares to expenses of $281,000, $669,000 and
$228,000 in these relative segment categories during the same period in 2004.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses remained steady at $1.7 million during the first six
months of 2005 and 2004. Increases in certain overhead costs such as investor
relations, professional services and depreciation coupled with increased
headcount in the U.S. were offset by decreased marketing expenses.
Other Income (Expenses). Other expenses increased $604,000 to $703,000 during
the first six months of 2005 from $99,000 during the same period in 2004. The
primary reason for the increase was an increase of $546,000 in interest expense
on debt financings we entered into during 2004 and 2003. Of this interest
expense, $330,000 and $97,000 in the first six months of 2005 and 2004,
respectively, was non-cash in nature related to the amortization of debt
issuance costs and discounts resulting from the warrants and beneficial
conversion features of the convertible debt. These increases were offset by an
increase of $104,000 in interest income resulting from maintaining a higher
balance of cash and investments during the second quarter of 2005 compared to
the same period in 2004. In addition, the first six months of 2005 included a
$142,000 non-cash increase in warrant liability resulting from the accounting
treatment for the warrants we issued in connection with the private placement of
convertible debt we completed in December 2004.
Liquidity and Capital Resources
Operating Activities. Cash used in operations increased $653,000 to $865,000
used during the first six months of 2005 compared to $213,000 used during the
same period in 2004. Working capital decreased $1.6 million to $8.8 million at
June 30, 2005 compared to $10.4 million at December 31, 2004. The current ratio
decreased to 8.0:1 at June 30, 2005 from 11.3:1 at December 31, 2004. The
decrease in working capital was primarily related to cash used in operations.
Cash and investment balances decreased to $8.8 million at June 30, 2005 from
$9.8 million at December 31, 2004, primarily as a result of cash used to fund
operating activities and service our debt during the first six months of 2005.
Accounts receivable decreased to $371,000 at June 30, 2005 from $412,000 at
December 31, 2004. The decrease was primarily a result of timing of purchases
and payments to EES. We expect overall receivable levels will continue to
fluctuate during 2005 depending on the timing of purchases and payments by EES
as well as the effects of sales of blood flow products.
Inventory levels decreased to $757,000 at June 30, 2005 compared to $855,000 at
December 31, 2004. We expect inventory levels to increase over the course of
2005 as we prepare to ramp up our blood flow business and reassess our safety
stock levels.
Investing Activities. Cash used in investing activities increased to $4.3
million during the first six months of 2005 from $55,000 during the same period
in 2004. We purchased $4.7 million and received $500,000 at maturity of
available-for-sale securities during the first six months of 2005. Capital
expenditures during the first six months of 2005 were split between purchases of
office equipment and production tools and equipment. Capital expenditures in the
first six months of 2004 were primarily related to purchases of technology
infrastructure. Capital needs for 2005 are still expected to be minor but should
increase somewhat over 2004 as we start up blood flow measurement device
production at our contract manufacturer.
Financing Activities. Financing activities used $113,000 in cash in the first
six months of 2005 versus $2.1 million provided during the same period in 2004.
16
Proceeds from the issuance of common stock were $58,000 and $2.3 million during
the first six months of 2005 and 2004, respectively. Payments of notes payable
were $155,000 and $159,000 during the first six months of 2005 and 2004,
respectively.
In November 2003, we executed common stock purchase agreements with certain
investors for the purchase of 12,173,914 shares of our common stock at a price
of $0.23 per share for net proceeds of $2.4 million. In addition, we issued the
purchasers warrants to purchase 6,086,959 shares of our common stock at an
exercise price of $0.28 per share, expiring in October 2008, and issued the
placement agents warrants to purchase 1,354,348 shares of our common stock on
similar terms. The per share value of these warrants was $0.31 on the date of
issuance using the Black-Scholes option pricing model with the following
assumptions: an average risk-free interest rate of 3.2%, volatility of 151% and
no expected dividend rate. During 2004, certain investors and placement agents
exercised a total of 3,230,066 warrants related to this placement resulting in
the issuance of 3,197,854 shares of our common stock and we realized net
proceeds of $871,398. During the first six months of 2005, certain investors and
placement agents exercised a total of 206,865 warrants and we realized proceeds
of $57,922.
In December 2004, we completed a private placement of Convertible Promissory
Notes in an aggregate principal amount of $8.1 million with Biomedical Value
Fund, L.P., Biomedical Offshore Value Fund, Ltd. and David C. Bupp (our
President and CEO). Biomedical Value Fund, L.P. and Biomedical Offshore Value
Fund, Ltd. are funds managed by Great Point Partners, LLC. The notes bear
interest at 8% per annum and are freely convertible into shares of our common
stock at a price of $0.40 per share. Neoprobe may force conversion of the notes
prior to their stated maturity under certain circumstances. The conversion price
represents the ten-day volume weighted average trading price of our common stock
through December 10, 2004. As part of this transaction, we issued the investors
10,125,000 Series T warrants to purchase our common stock at an exercise price
of $0.46, expiring in December 2009. The fair value of the warrants issued to
the investors was $1,315,000 on the date of issuance and was determined by a
third-party valuation firm using the Black-Scholes option pricing model with the
following assumptions: an average risk-free interest rate of 3.4%, volatility of
50% and no expected dividend rate. In connection with this financing, we also
issued 1,600,000 Series U warrants to purchase our common stock to the placement
agents, containing substantially identical terms to the warrants issued to the
investors. The fair value of the warrants issued to the placement agents was
$208,014 using the Black-Scholes option pricing model with the same assumptions
used to determine the fair value of the warrants issued to the investors. The
value of the beneficial conversion feature of the notes was estimated at
$1,315,000 based on the effective conversion price at the date of issuance.
Our future liquidity and capital requirements will depend on a number of
factors, including our ability to raise additional capital in a timely manner
through additional investment, expanded market acceptance of our current
products, our ability to complete the commercialization of new products, our
ability to monetize our investment in non-core technologies, our ability to
obtain milestone or development funds from potential development and
distribution partners, regulatory actions by FDA and other international
regulatory bodies, and intellectual property protection. We believe we now have
adequate capital to assure that we can properly support our current business
goals and objectives for 2005 and into 2006. Our near-term priorities to
commence multi-center trials for our Lymphoseek product, support the launch of
the reengineered version of the Quantix/OR products, identify a development and
commercialization partner for our RIGS technology, complete a technology
assessment of our ACT technology and continue to innovate our gamma detection
product line. We cannot assure you that we will be able to achieve significant
product revenues from our current or potential new products. We also cannot
assure you that we will achieve profitability again.
Recent Accounting Developments
In November 2004, the Financial Accounting Standards Board (FASB) issued SFAS
No. 151, Inventory Costs, an amendment of ARB No. 43, Chapter 4. This statement
amends the guidance in ARB No. 43 Chapter 4, Inventory Pricing, to clarify the
accounting for abnormal amounts of idle facility expense, freight, handling
costs, and wasted material (spoilage). Paragraph 5 of ARB No. 43, Chapter 4,
17
previously stated that " . . . under some circumstances, items such as idle
facility expense, excessive spoilage, double freight, and rehandling costs may
be so abnormal to require treatment as a current period charge...." This
statement requires that those items be recognized as current-period charges
regardless of whether they meet the criterion of "so abnormal." In addition,
this statement requires that allocation of fixed production overheads to the
costs of conversion be based on the normal capacity of the production
facilities. The provisions of this statement will be effective for inventory
costs during fiscal years beginning after June 15, 2005. Neoprobe does not
believe that the adoption of this statement will have a material impact on our
consolidated financial condition or results of operations.
In December 2004, the FASB issued SFAS No. 123R (revised 2004), Share-Based
Payment, which is a revision of SFAS No. 123, Accounting for Stock-Based
Compensation (SFAS No. 123R). SFAS No. 123R supersedes APB Opinion No. 25,
Accounting for Stock Issued to Employees, and amends SFAS No. 95, Statement of
Cash Flows. Generally, the approach in SFAS No. 123R is similar to the approach
described in SFAS No. 123. However, SFAS No. 123R requires all share-based
payments to employees, including grants of employee stock options, to be
recognized in the income statement based on their fair values. Pro forma
disclosure is no longer an alternative. SFAS No. 123R provides for a prospective
application. Under this method, we will begin recognizing compensation expense
for equity-based compensation for all new or modified grants after the date of
adoption. In addition, we will recognize the unvested portion of the grant date
fair value of awards issued prior to adoption based on the fair values
previously calculated for disclosure purposes. We expect to adopt SFAS No. 123R
on January 1, 2006.
As permitted by SFAS No. 123, Neoprobe currently accounts for share-based
payments to employees using APB Opinion No. 25's intrinsic value method and, as
such, generally recognizes no compensation cost for employee stock options.
Accordingly, the adoption of SFAS No. 123R's fair value method will have a
significant impact on our result of operations, although it will have no impact
on our overall cash position. The impact of adoption of SFAS No. 123R cannot be
predicted at this time because it will depend on levels of share-based payments
granted in the future and the assumptions for the variables which impact the
computation. However, had we adopted SFAS No. 123R in prior periods, the impact
of that standard would have approximated the impact of SFAS No. 123 as described
in the disclosure of pro forma net loss and loss per share in Note 2 to our
consolidated financial statements. SFAS No. 123R also requires the benefits of
tax deductions in excess of recognized compensation cost to be reported as a
financing cash flow, rather than as an operating cash flow as required under
current literature.
In December 2004, the FASB issued SFAS No. 153, Exchanges of Nonmonetary
Assets--An Amendment of APB Opinion No. 29, Accounting for Nonmonetary
Transactions (SFAS No. 153). SFAS No. 153 eliminates the exception from fair
value measurement for nonmonetary exchanges of similar productive assets in
paragraph 21(b) of APB Opinion No. 29, Accounting for Nonmonetary Transactions,
and replaces it with an exception for exchanges that do not have commercial
substance. SFAS No. 153 specifies that a nonmonetary exchange has commercial
substance if the future cash flows of the entity are expected to change
significantly as a result of the exchange. SFAS No. 153 is effective for fiscal
periods beginning after June 15, 2005 and is required to be adopted by Neoprobe
beginning January 1, 2006. Neoprobe is currently evaluating the effect that the
adoption of SFAS No. 153 will have on its consolidated results of operations and
financial condition but does not expect it to have a material impact.
Critical Accounting Policies
The following accounting policies are considered by us to be critical to our
results of operations and financial condition.
Revenue Recognition Related to Net Sales. We currently generate revenue
primarily from sales of our gamma detection products; however, sales of blood
flow products constituted approximately 5% of total revenues for the first six
months of 2005 and are expected to increase in the future. We generally
recognize sales revenue related to sales of our products when the products are
shipped and the earnings process has been completed. Our customers have no right
to return products purchased in the ordinary course of business. However, in
cases where product is shipped but the earnings process is not yet completed,
18
revenue is deferred until it has been determined that the earnings process has
been completed. The prices we charge our primary gamma detection device
customer, EES, related to sales of products are subject to retroactive annual
adjustment based on a fixed percentage of the actual sales prices achieved by
EES on sales to end customers made during each fiscal year. To the extent that
we can reasonably estimate the end-customer prices received by EES, we record
sales to EES based upon these estimates. If we are unable to reasonably estimate
end customer sales prices related to certain products sold to EES, we record
revenue related to these product sales at the minimum (i.e., floor) price
provided for under our distribution agreement with EES.
We also generate revenue from the service and repair of out-of-warranty
products. Fees charged for service and repair on products not covered by an
extended service agreement are recognized upon completion of the service process
when the serviced or repaired product has been returned to the customer. Fees
charged for service or repair of products covered by an extended warranty
agreement are deferred and recognized as revenue ratably over the life of the
extended service agreement.
Use of Estimates. The preparation of financial statements in conformity with
U.S. generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosures of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. We base these estimates and assumptions upon
historical experience and existing, known circumstances. Actual results could
differ from those estimates. Specifically, management may make significant
estimates in the following areas:
o Allowance for Doubtful Accounts. We maintain an allowance for doubtful
accounts receivable to cover estimated losses resulting from the inability
of our customers to make required payments. We determine the adequacy of
this allowance by regularly reviewing our accounts receivable aging and
evaluating individual customer receivables, considering customers' credit
and financial condition, payment history and relevant economic conditions.
If the financial condition of our customers were to deteriorate, resulting
in an impairment of their ability to make payments, additional allowances
for doubtful accounts may be required.
o Inventory Valuation. We value our inventory at the lower of cost
(first-in, first-out method) or market. Our valuation reflects our
estimates of excess, slow moving and obsolete inventory as well as
inventory with a carrying value in excess of its net realizable value.
Write-offs are recorded when product is removed from saleable inventory.
We review inventory on hand at least quarterly and record provisions for
excess and obsolete inventory based on several factors, including current
assessment of future product demand, anticipated release of new products
into the market, historical experience and product expiration. Our
industry is characterized by rapid product development and frequent new
product introductions. Uncertain timing of product approvals, variability
in product launch strategies, product recalls and variation in product
utilization all impact the estimates related to excess and obsolete
inventory.
o Impairment or Disposal of Long-Lived Assets. We account for long-lived
assets in accordance with the provisions of SFAS No. 144. This Statement
requires that long-lived assets and certain identifiable intangibles be
reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The
recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to future net undiscounted cash flows
expected to be generated by the asset. If such assets are considered to be
impaired, the impairment to be recognized is measured by the amount by
which the carrying amount of the assets exceeds the fair value of the
assets. Assets to be disposed of are reported at the lower of the carrying
amount or fair value less costs to sell. As of June 30, 2005, the most
significant long-lived assets on our balance sheet relate to assets
recorded in connection with the acquisition of Cardiosonix and gamma
detection device patents related to intraoperative lymphatic mapping. The
recoverability of these assets is based on the financial projections and
models related to the future sales success of Cardiosonix' products and
the continuing success of our gamma detection product line. As such, these
assets could be subject to significant adjustment should the Cardiosonix
technology not be successfully commercialized or the sales amounts in our
current projections not be realized.
19
o Product Warranty. We warrant our products against defects in design,
materials, and workmanship generally for a period of one year from the
date of sale to the end customer. Our accrual for warranty expenses is
adjusted periodically to reflect actual experience. EES also reimburses us
for a portion of warranty expense incurred based on end customer sales
they make during a given fiscal year.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe
harbor for forward-looking statements made by or on behalf of our company. From
time to time, our representatives and we may make written or verbal
forward-looking statements, including statements contained in this report and
other company filings with the SEC and in our reports to stockholders.
Statements that relate to other than strictly historical facts, such as
statements about our plans and strategies, expectations for future financial
performance, new and existing products and technologies, anticipated clinical
and regulatory pathways, and markets for our products are forward-looking
statements within the meaning of the Act. Generally, the words "believe,"
"expect," "intend," "estimate," "anticipate," "will" and other similar
expressions identify forward-looking statements. The forward-looking statements
are and will be based on our then-current views and assumptions regarding future
events and operating performance, and speak only as of their dates. Investors
are cautioned that such statements involve risks and uncertainties that could
cause actual results to differ materially from historical or anticipated results
due to many factors including, but not limited to, our continuing operating
losses, uncertainty of market acceptance of our products, reliance on third
party manufacturers, accumulated deficit, future capital needs, uncertainty of
capital funding, dependence on limited product line and distribution channels,
competition, limited marketing and manufacturing experience, risks of
development of new products, regulatory risks, and other risks detailed in our
most recent Annual Report on Form 10-KSB and other SEC filings. We undertake no
obligation to publicly update or revise any forward-looking statements.
Item 3. Controls and Procedures
As of the end of the period covered by this report, we carried out an
evaluation, under the supervision and with the participation of management,
including our Chief Executive Officer and Chief Financial Officer, of the
effectiveness of the design and operation of our disclosure controls and
procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, the
Chief Executive Officer, along with the Chief Financial Officer, concluded that
our disclosure controls and procedures are effective in timely alerting them to
material information relating to our company (including our consolidated
subsidiaries) required to be included in our periodic SEC filings. There were no
changes in our internal control over financial reporting that occurred during
our most recent fiscal quarter that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.
20
PART II - OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders
(a) Neoprobe Corporation held its Annual Meeting of Stockholders on June 13,
2005, for the purpose of electing two directors, increasing the authorized
number of shares of the company's stock, and amending the company's 2002
Stock Incentive Plan.
(b) At the Annual Meeting of Stockholders, the directors nominated were
elected.
(c) The following table shows the voting tabulation for each matter voted upon
at the Annual Meeting of Stockholders.
ACTION FOR WITHHELD
------ ---------- ---------
Election of Directors
Carl J. Aschinger, Jr. 45,741,306 1,838,234
Fred B. Miller 45,754,361 1,825,179
ACTION FOR AGAINST ABSTAIN
---------- --------- -------
Increase the authorized number of shares
of the company from 105,000,000 to 155,000,000,
consisting of 150,000,000 shares of common stock,
$.001 par and 5,000,000 shares of preferred stock,
$.001 par value 42,671,721 4,704,066 203,753
ACTION FOR AGAINST ABSTAIN
--------- --------- -------
Amend the 2002 Stock Incentive Plan to increase
the number of shares of common stock issuable
under the plan from 3,000,000 to 5,000,000 shares 9,618,474 5,053,544 133,291
--------- --------- -------
Item 6. Exhibits
3.1 Restated Certificate of Incorporation of Neoprobe Corporation as
corrected February 18, 1994 and amended June 27, 1994, June 3, 1996,
March 17, 1999, May 9, 2000, June 13, 2003, July 27, 2004 and June
22, 2005.
31.1 Certification of Chief Executive Officer pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer of Periodic Financial
Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350
32.2 Certification of Chief Financial Officer of Periodic Financial
Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350
Items 1, 2, 3, and 5 are not applicable and have been omitted.
21
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
NEOPROBE CORPORATION
(the Company)
Dated: August 15, 2005
By: /s/ DAVID C. BUPP
----------------------------------------
David C. Bupp
President and Chief Executive Officer
(duly authorized officer; principal executive officer)
By: /s/ BRENT L. LARSON
-------------------------------
Brent L. Larson
Vice President, Finance and Chief Financial Officer
(principal financial and accounting officer)
22